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ABSTRACT
In recent years bacteria have become increasingly resistant to antibiotics, leading to a decline in
the effectiveness of antibiotics in treating infectious disease.  This paper uses a framework based
on an epidemiological model of infection in which antibiotic effectiveness is treated as a non-
renewable resource.  In the model presented, bacterial resistance (the converse of effectiveness)
develops as a result of selective pressure on non-resistant strains due to antibiotic use.  When two
antibiotics differ only in quality, it is optimal to use one antibiotic initially, following which it is
optimal to switch to a combination of the two drugs.  The optimal proportion and timing of use
for the two antibiotics depends precisely on the difference between the rates at which bacterial
resistance to each antibiotic evolves and on the differences in their pharmaceutical costs, results
that are unique in the literature on antibiotic resistance.  We use standard numerical techniques to
illustrate cases for which the analytical problem is intractable. JEL Classification Codes: Q3, I1.
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1. INTRODUCTION
The issue of resistance is a recurring theme in any attempt to curb organisms that are harmful to
humans and human enterprise.  Bacteria develop resistance to antibiotics
2, malarial parasites to
anti-malarial drugs, and pests to pesticides.  The problem of resistance represents an externality
associated with the use of antibiotics, anti-malarial drugs or pesticides.  Associated with each
beneficial application of these treatments is the increased likelihood that they will be less effective
for oneself and for others when used in the future. Alexander Fleming, who discovered penicillin
in 1928, was among the first to recognize the potential for bacteria to develop resistance. In
recent times, with the evolution of multi-drug resistant strains of bacteria such as Vancomycin-
resistant Staphylococcus aureus (VRSA) and multi-drug resistant Streptococcus pneumoniae, it is
no longer possible to treat infections that were commonly treated using antibiotics only a few
years ago.  For instance gonorrhea, a disease that was commonly treated using penicillin, has now
become almost completely resistant to that drug.
The prospect of a post-antibiotic era in which most common disease causing bacteria are
resistant to available antibiotics has been a topic of much speculation.  In an address to the Irving
Trust in 1994, Nobel laureate Joshua Lederberg declared
 “We are running out of bullets for dealing with a number of (bacterial) infections.  Patients are
dying because we no longer in many cases have antibiotics that work.”
 3
In fact, studies in the medical literature have shown conclusively that patients infected with drug-
resistant organisms are more likely to require hospitalization, to have a longer hospital stay and,
to die
4.
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Despite the huge potential consequences of antibiotic resistance to the treatment and cure
of infectious diseases, the costs of resistance are not internalized during the process of antibiotic
treatment.  The evolution of antibiotic resistance is strongly influenced by the economic behavior
of individuals and institutions.  The more antibiotics are used (or misused), the greater the
selective pressure placed on bacteria to evolve.  The problem, therefore, arises from the absence
of economic incentives for individuals to take into account the negative impact of their use of
antibiotics on social welfare.  The economics literature on the topic of bacterial resistance is
limited to a 1996 paper by Brown and Layton in which resistance is modeled as a dynamic
externality (Brown and Layton, 1996).  Hueth et. al. model pest susceptibility (to pesticides) as a
stock of non-renewable natural resource that is costless to use in the short run but extremely
expensive to replace in the long run (Hueth and Regev, 1974).  Adopting this approach of treating
susceptibility as an exhaustible resource in a study on the optimal management of pest resistance,
Comins found that the cost of resistance is analytically equivalent to an increase in the cost of the
pesticide (Comins, 1979, Comins, 1977).
Our purpose is to derive the optimal antibiotic treatment policy recognizing that both the
rate of infection and the effectiveness of antibiotics decline with antibiotic use.  The model
presented in this paper has two physical components.  First, there is a version of the Kermack-
McKendrick SIS model of disease transmission in which individuals move between susceptible
and infected states
5. This model describes the dynamics of infection when antibiotic treatment is
used (Kermack and McKendrick, 1927).  These equations were first used in 1915 by Sir Ronald
Ross to describe the epidemic spread of malaria (Ross, 1915). Second, we derive the equations
describing the evolution of antibiotic resistance by imposing certain biological attributes of
resistant and sensitive strains of bacteria on the SIS model.  The problem posed is one of optimal
use of a non-renewable resource.  In a simple non-renewable resource model with variable costs
of drugs omitted, the drug with the most effectiveness should be used exclusively until the level of
resistance (effectiveness) is the same for each antibiotic.  Then each drug should be used in
precise proportion to the rate that use deteriorates the respective capital stock of effectiveness.
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These results differ in general from those in the only comparable paper written by natural
scientists (Bonhoeffer, et al., 1997)
6.   Unlike their epidemiological model that simulates
alternative treatment strategies, long-term benefits do depend on the policy of antibiotic use and
using two antibiotics in a 50/50 ratio is not an optimal proportion to propose in general.  We
describe the circumstances under which resistance may be treated as a non-renewable resource
and also those circumstances under which a model applicable to a renewable resource is more
relevant.  We then use antibiotic use and bacterial resistance data from Harborview Medical
Center, Seattle to estimate key parameters in the theoretical model.  Results from the empirical
section support the theoretical model.  After a period of single drug use, it is optimal to use the
two antibiotics simultaneously.  In contrast to ores of different qualities, antibiotics with different
vulnerabilities to resistance contribute equally (marginally) to the control of infection and the
optimal share keeps the resistance level of each drug in equality.
The organization of this paper is as follows.  Section 2 provides an overview of the issue
of resistance, its biological nuances and key features.  Section 3 contains a description of the SIS
model of disease transmission
7, and a derivation of the model of antibiotic resistance.  It also
describes the economic problem of optimal antibiotic use when antibiotic effectiveness is treated
as a non-renewable resource.  Section 4 presents the results obtained from numerical techniques
based on economic and biological parameters.  Section 5 concludes the paper.
2. ANTIBIOTIC RESISTANCE
Antibiotic resistance is usually an outcome of natural selection.  Nature endows all bacteria with
some low level of resistance.  Thus a small fraction of the bacteria, in the order of one in a million,
is naturally resistant to the antibiotic.  Many studies have shown that the existence of these
resistant strains predates the use of antibiotics as a treatment for infectious disease (Levy, 1992).
When an antibiotic is used to treat a bacterial infection, only the bacteria that are susceptible to
the antibiotic are killed while the small fraction of resistant bacteria survive.  Therefore, the use of
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antibiotics gives a selective advantage to the resistant bacteria and over time, the bacterial
population is composed entirely of these resistant strains. Treatment of these resistant populations
using antibiotics is then quite ineffective.
Natural selection is not the only mechanism by which resistance evolves.  Bacteria possess
the ability to directly transfer genetic material between each other using a mechanism known as
plasmid transfer.  Plasmids are packets of genetic material that serve as a vehicle for the transfer
of resistance between different bacterial species.  They are believed to be responsible for the
geographical spread of resistance from regions of the world where bacterial resistance has
occurred to other regions.  A third mechanism by which resistance is induced in bacteria is by
mutation.  By this process, bacteria spontaneously change their genetic composition in response
to an attack by antibiotics.  Over time, the continued use of antibiotics encourages greater levels
of mutation, leading to high levels of bacterial resistance.
The increase in bacterial resistance in hospitals and in communities has been attributed to a
number of reasons.  In hospitals, the use of broad-spectrum antibiotics and the use of antibiotics
as prophylaxis, i.e. preventive cure before surgery, have contributed to resistance.  Since resistant
bacteria spread in the same ways as those of normal bacteria, the failure to introduce sufficient
infection control methods has contributed to the quick spread of resistant strains.  An important
reason for the observed increase in antibiotic resistance in the community has been the overuse of
antibiotics in the community.  This is partly due to the easy availability of antibiotics, sometimes
even without a prescription in some parts of the world.  Even in countries where antibiotics are
sold only under prescription, there are few economic incentives for doctors to prescribe
antibiotics responsibly.  In addition, the failure of patients to complete a full cycle of antibiotic
treatment allows a few bacteria in their system to survive with a better ability to deal with
antibiotics in the future.  Finally, the use of antibiotics in cattle feed as growth promoters
encourages antibiotic resistance (Levy, 1992).
The problem of antibiotic resistance is complex and difficult to model in its entirety.  In
this paper, we rely on a few stylized facts about the mechanisms and issues that contribute to
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resistance.  One such abstraction is that the increased use of antibiotics leads to increased
resistance.  This feature permits us to treat the problem of increasing resistance (or decreasing
effectiveness) as a problem of optimal extraction of a non-renewable natural resource (Carlson,
1972, Hueth and Regev, 1974).  Although a number of other factors contribute to resistance, such
as inappropriate use of antibiotics, lack of sufficient infection control methods, and failure by
patients to complete a full cycle of treatment, an analysis of the economic incentives that influence
these other factors lies outside the scope of this paper.  For the purpose of this analysis, we shall
assume that bacterial resistance evolves through natural selection.  For one, the science and
mechanisms for natural selection are well understood in the biology literature.  Second, there is
little understanding about the rate of transmission of transposons (plasmid transfer) and the
environmental factors that encourage such transfers.  In fact, a number of bacterial strains such as
Citrobacter freundii, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris and Serratia, do
not acquire resistance by transfer of plasmids most of the time (Amabile-Cuevas, 1996).
A number of studies have demonstrated conclusively that the development of bacterial
resistance to antibiotics is correlated with the level of antibiotic use (Cohen and Tartasky, 1997,
Hanberger, et al., 1997, Muder, et al., 1997).  In a comprehensive survey of the medical literature
on antibiotic resistance, McGowan lists studies that have found associations between increased
antibiotic use and increased resistance, as well as decreased antibiotic use and decreased
resistance (McGowan, 1983).  He notes that resistance is more common in the case of hospital
acquired infections than in community acquired infections.  This is not surprising considering that
antibiotic use in hospitals is relatively intensive compared to use in the community.  Second, areas
in the hospitals where antibiotic use is more intensive are more likely to be sources of resistant
bacteria.  Further, the likelihood that patients will be infected with resistant bacteria increases with
duration of hospitalization.  These results indicate the presence of a causal relationship between
antibiotic use and resistance.  Moreover, studies have shown that the likelihood of resistance
developing in a patient with a history of antibiotic use is greater than in a patient who has been
unexposed to antibiotics.  Strategies to improve antibiotic use include the use of  “antibiograms”
which provide information on the susceptibility of common bacteria to antibiotics; use of
formularies, which restrict the menu of antibiotics available to the physician to prescribe from;7
sequestration of nursing staff; computerized monitoring of prescribing behavior, and physician
education.
Should antibiotic effectiveness be considered a renewable or a depletable resource?
Antibiotic resistant strains of bacteria are, by definition, more likely than sensitive strains to
survive a treatment of antibiotics.  Fortunately for humans, these resistant strains may be at a
comparative disadvantage for survival in an environment free of antibiotics.  This disadvantage is
known as the fitness cost of antibiotic resistance.  Mathematically, the fitness cost is a measure of
the rate at which the bacteria regresses to susceptibility in the absence of antibiotic treatment.
The question of evolutionary disadvantage imposed by resistance is an important one from the
standpoint of natural resources modeling.  If resistant strains are less able to survive when the use
of antibiotics is suspended, then there may be a steady state in which the loss of antibiotic
effectiveness is just matched by the rate at which it recovers due to the fitness cost of resistance,
albeit at a rate consistent with high rates of unmitigated infection.  This problem is analogous to
the one of optimal fish harvesting.  It is conceivable that an antibiotic may have cycles of useful
life and some studies have demonstrated the possibility of cycling in the case of pesticide
resistance.  However, the time taken for antibiotics to recover their effectiveness is much longer
than the time it took for the initial loss of effectiveness.  Moreover, resistance evolves much faster
when the antibiotic is reintroduced than during the initial cycle of use (Anderson and May, 1991).
3.   THE BIOLOGY AND ECONOMICS OF RESISTANCE
This paper examines the question of the optimal use of two antibiotics in a hospital setting.  We
find that the results obtained from an analysis of the economic problem of optimal antibiotic use
differ from results that would be obtained from either biological models, or ore extraction models
alone.  On the one hand, biological models ignore economic costs and suggest that it is optimal to
use both antibiotics simultaneously at all times. On the other hand, ore extraction models suggest
that one ought to use the less costly antibiotic to begin with, and switch to the more costly
antibiotic when the effectiveness of the first antibiotic is fully exhausted.8
Two essential building blocks in our model are setting forth the dynamics of both infection
and antibiotic effectiveness (resistance) in a manner that is both faithful to epidemiological ground
truth as well as amenable to economic analysis.  That is the task to which we now turn, after
which we add the economic components.
3.1 Biology
The basic SIS model of infectious disease was introduced by Kermack and McKendrick in
1920 and is commonly used in epidemiological studies of infectious diseases (Kermack and
McKendrick, 1927). We use a modified version of this model in order to incorporate the dynamics
of resistance.  There are two primary states in this model, Susceptible and Infected.  The infected
population is, in turn, characterized by infection either with a sensitive strain or with a resistant
strain of bacteria.  Individuals who are infected with the sensitive strain are cured faster through
antibiotic treatment.  Those with a resistant strain also recover, albeit at a slower rate defined as
the spontaneous rate of recovery.  The equation governing the rate of change of infection is
(1)  ( ) fI rI I I I - - - = 1 b &
Figure 1 illustrates the SIS model where  f  is the fraction of the infected population
treated with a single antibiotic.
Consider the dynamics of infection and resistance to a single antibiotic in a hospital




S I I r I r I fI w r w w r r w = - + + + + b
where S  is the uninfected (healthy) fraction of the population.  S I & & - =  since  S I - =1 , and
r w I I I + =  where  Iw  denotes the fraction of the population infected with the sensitive (wild-
type) strain and Ir  refers to the fraction infected with the resistant strain. Both rw and rr refer to
the spontaneous (no treatment) rate of recovery of an infected individual.  The spontaneous rate
of recovery of the infected population is either rw or rr depending on whether they are infected9
with a sensitive or a resistant organism respectively.
8  Due to the fitness cost imposed on resistant
strains, the spontaneous rate of recovery from a sensitive strain is expected to not exceed the rate
of recovery from a resistant strain.  Thus fitness cost is denoted by  0 ‡ - = D w r r r r
9.
The dynamic changes in the population infected with sensitive and resistant strains are
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Thus w is good capital in the sense that it is used to treat the consequences of infection whereas
infection is taken to be bad capital.  Making appropriate substitutions using equations (1)-(4)
yields
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For the purpose of this paper, we assume in the text that  0 = Dr  because we want to analyze the
case when antibiotic effectiveness is a depletable resource. This scenario is described in a recent
study which showed that while bacterial strains resistant to antibiotics are initially less virulent
than their susceptible counterparts, they acquire virulence rapidly without any loss of their
resistance (Bjorkman, et al., 1998).  The natural rate of recovery of an infected individual from a
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resistant strain is therefore, the same as his/her rate of recovery from a susceptible strain.  A static
overall absolute size of population is assumed, without loss of generality.
Equation (5.2) indicates that w  decreases with the antibiotic use.  The decrease in w is
analogous to the case of declining ore quality in the case of mineral extraction.  It is well known
that declining ore quality is the conceptual twin of the case of increasing cost of extraction.
Resistance can therefore be thought of as a cost associated with the use of antibiotics.  However,
unlike the case of oil, the decline of antibiotic effectiveness, represented by (5.2), is a non-linear
(specifically, logistic) function of use.  This feature of the extraction in our model has the visual
equivalence of an hour-glass shaped well of antibiotic effectiveness.  We see that  w w ¶ ¶&  is
positive until w = 0.5 and is negative thereafter.
10
Further assumptions are necessary in order to shape the analytical model so that key ideas
have prominence. We also assume that both cross-resistance (the effect of using antibiotic 1 on
bacterial resistance to antibiotic 2) and multi-drug resistance (simultaneous resistance to both
antibiotics) are negligible.  Two standard assumptions that accompany the basis SIS model are
applicable here.  Immunity is ruled out and an individual is susceptible to infection immediately
after successful treatment.  We also rule out super-infection, thereby assuming that an infected
individual is not at risk for a secondary infection.  This assumption is a reasonable one to make for
a small, infected population (Bonhoeffer, et al., 1997).  We further assume that resistance has
already been introduced into the infected population and that a small sub-population of infectives
carries the resistant strain.  The initial effectiveness of the antibiotics is denoted by  0 w  where
1 0 » w .  The model is generally applicable to infections such as tuberculosis, Pseudomonas and
gonorrhea in which the organism that causes infection is not normally present in the host
11.
                                                       























11 Some infection causing organisms such as E. Coli and Pneumococci are generally present in the intestine, nasal cavity etc.
without infecting the host.  A different model is applicable to the evolution of resistance in these “commensal” organisms.11
3.2 Economics
The benefit for each antibiotic i used is  ( ) ( ) ( ) t I t f t bw i i , where b  is the benefit associated with
each successful treatment using the antibiotic measured in $/person, scaled both by the fraction of
( ) t I  treated and the effectiveness, ( ) t wi , of such treatment.  The cost associated with the infection
is represented by  ( ) t I cI .  The inter-temporal net benefit function is
(6)  ( ) ( ) ( ) ( ) ( ) ( ) , max
0



















where c  is the unit cost of treatment with antibiotic 2 and the cost of antibiotic 1 is assumed to be
0
12.  Time subscripts are suppressed for clarity in the following analysis.
We treat potentially with two antibiotics, whose resistance dynamics are derived in
Appendix 1, and modified by assumption that  0 = Dr  are described by
(7.1) ( ) 1 1 1 1 1 - = w kw f w &
(7.2) ( ) 1 2 2 2 2 - = w w f w &
Here  ( ) 1 < k  is a factor introduced to distinguish the resistance profile of antibiotic 1 from
antibiotic 2.  Thus using antibiotic 1 decreases future effectiveness less than treating an identical
fraction of patients with antibiotic 2.
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i i c t f c t f t w b  to ensure that the objective function is non-increasing in the
level of infection.
13 wfI becomes  ￿ i i f w I when more than one antibiotic can be used.  Further, in the absence of fitness costs,  r r in
equation (5.1) is denoted by  .12
1 and  1 0 £ £ i f
where  r  is the social discount rate and costate variables  1 m ,  2 m  and j  are associated with  1 w ,
2 w  and I respectively.  We further assume that no patient is treated with both antibiotics
simultaneously.   Therefore,  1 £ i f  and  1 £ S i f  are constraints harmlessly omitted from (8) as
will become clear in the ensuing discussion.  Relevant necessary conditions for a maximization of
(8) are as follows,
































w k I b as f m j  for  0 1 „ w ,





































I b as f m j for  0 2 „ w ,
(8.3) ( ) ( ) 1 1 1 1 1 1 2 1 m rm m j & - = - - - w kf If b
(8.4) ( ) ( ) 2 2 2 2 2 2 2 1 m rm m j & - = - - - w f If b
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plus the transversality conditions
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The economic interpretation of (8.1) after rewriting as
(10) ( ) 1 1 1 1 1 1 w w Iw bIw - = - m j13
is that the marginal benefit of changing the fraction of the population treated using antibiotic 1
equals its marginal cost.  Since j  is the costate variable for infection, a bad,  0 < j  which is







The relevant marginal unit here is not a person but a fraction of the infected population
treated.  Marginal use of an antibiotic does two good things.  It cures, conferring benefit of b  to
the individual, scaled by the effective fraction successfully treated, ( 1 Iw ). It also reduces the stock
of infection, conferring a benefit of  1 Iw j  to society.  The user cost or rental rate for a unit of
"effectiveness" capital is  1 m  for antibiotic 1.  In traditional renewable resource models, there is an
opportunity cost of reducing resources by a unit.  In this model, changing the fraction of people
treated reduces the growth equation of effectiveness by w &  when 1 1 = f , so the population
effectively treated must see this cost,  1 1w & m .  When  1 2 = f , the economic interpretation of (8.2) is
the same, but for the addition of a cost term.
To understand the economic anatomy of this model, it is useful to move from simpler to
more complex cases.
Case 1:  0 = = c cI
There are two important segments along the optimal path in this model, when the effectiveness of
the two antibiotics is the same,  2 1 w w =  and when they differ.  We prove in Appendix 3 that the
necessary condition for both the antibiotics to be used simultaneously is  2 1 w w = .  This condition
holds along the optimal path as the effectiveness of each drug declines asymptotically towards
zero.
When, say  1 2 w w > , it pays to draw down  2 w  as rapidly as possible until it reaches  1 w ,
setting  1 2 = f .  There are three explanations in support of this reasoning.  First, the value of the14
marginal product of each antibiotic, ( ) i Iw b j -  decreases as  i w decreases, so it pays to use the
antibiotic with the highest effectiveness first.  Second, since from (5.1), I &  is inversely and linearly
related to antibiotic effectiveness ( ) i w , the biggest impact on reducing infection is achieved by
using the antibiotic with the biggest w .  Note that there is a capacity constraint with a maximum
value of  1 2 = f  and hence  0 1 = f .  The length of time T  during which only drug 2 is used, is
readily calculated from antibiotic 2’s resistance dynamics in (7.2) and our knowledge of  ( ) 0 1 w ,
( ) 0 2 w  and when both are used,  ( ) ( ) T w w 2 1 0 = .  Solve for

















Finally, if the lower effectiveness drug ( ) 1 w  is used first,  1 w  would decrease
asymptotically toward zero and there never would be a time when  2 1 w w = .  Consequently, the
most effective drug would never be used.  Moreover,  2 m  rises at the rate of interest when
antibiotic 2 is not in use (evaluate (8.4) for  0 2 = f ) so the transversality conditions for  2 w are
violated.
How should each antibiotic be used when  w w w = = 2 1 ?  From (7.1) and (7.2),



























since  1 2 1 £ + f f  where the equality holds because the Hamiltonian is linear in  i f and therefore,
use should be the maximum permissible.  Using the ore analogy to understand antibiotics breaks
down here.  While it is sometimes optimal to use two antibiotics simultaneously, it is not optimal
to use ores of different grades simultaneously.15
Since  1 < k , a greater fraction of the infected population is treated with drug 1 because a
given dose reduces effectiveness (increases resistance) less than does drug 2.  For this reason, the
rental rate on  1 w  exceeds the rental rate on  2 w  as manipulation of (8.1) and (8.2) demonstrates.
When both antibiotics are in use, the rental rate rises slower than the discount rate.  Using (8.1)-












The result follows naturally from recognizing that antibiotics are Ricardian resources with the
quality of each decreasing with use over time.
Figure 2 summarizes the optimal path of  1 w  and  2 w , when  2 1 w w = .  Combining (7.1) or (7.2)
with (13) yields









along the path of joint use, and so the level of effectiveness at any time t after joint use has
started at time normalized at  0 = t is
























It is a little curious that the amount each antibiotic should be used (equation (13)) and the
optimal paths of effectiveness (given by equation (14.3)) are independent of economic variables.
Natural scientists, such as Bonhoeffer et. al., do not use dynamic optimization, but rather use
static optimization and simulations to choose protocols such as equal proportions of infected
persons receiving each drug instead of cycling or multiple drug use simultaneously.  Such a
protocol varies in general from the results of our optimization procedure. Put differently,16
intertemporal optimization, not economic parameters drive the results in this problem; these
results differ from treatments of the same problem by non-economists.
Case 2:  0 , 1 > = c k
The case when  0 > c  is importantly different for two reasons.  Letting  1 = k , and starting
out with  ( ) ( ) 0 0 2 1 w w = , resource 1 is cheaper to use initially and so should be used first.  In the
initial stages, the results resemble the solution for ores of different qualities (Hartwick, 1978).
However, using antibiotic 1, reduces its effectiveness which, in turn reduces benefit such that
2 1 bw bw < .  When this loss cannot compensate for the higher marginal cost c , it pays to
introduce drug 2 as well, a result that is compatible with the policy of using two ores of different
qualities.
The second reason this case is potentially important is that it contrasts with the Bonhoeffer et. al.
result that two drugs should always be used, a conclusion reached by limiting the model to
biological variables i.e. omitting economic variables.
The interpretation of (8.2) with variable costs is straightforward.  In each time period, the
marginal benefit of treatment with antibiotic 2 (represented by the first term) should equal the
marginal out of pocket expense,  I c , plus the marginal user cost of drawing down the stock of
antibiotic 2's effectiveness capital.  The marginal user cost of treatment captures the future
opportunity cost of increasing resistance.  If the marginal benefit of antibiotic treatment is less
than the user cost of antibiotics, then that antibiotic should not be used.17
4. CASE STUDY: AMINOGLYCOSIDE USE AT HARBORVIEW MEDICAL CENTER
We extend our demonstration of the divergence between results obtained from purely
epidemiological models and other models that combine economics with epidemiology, for cases
that are more complex than the ones considered so far.  In order to do this, we use numerical
computations to trace out the optimal extraction paths of antibiotic effectiveness and the paths of
costate variables.  Parameter values used in the numerical computations were estimated in an
earlier study and are contained in Table 1 (Laxminarayan and Brown, 1998).  These estimates
were based on monthly data on the resistance of Pseudomonas aeruginosa (PSAR), to two
commonly used antibiotics, Gentamicin (GENT) and Tobramycin (TOB) over a 12 year period
from January 1, 1985 through December 31, 1996.  These data from Harborview Medical Center
in Seattle were complemented by pharmacy data on antibiotic prescriptions during this period.
Although the fitness cost of resistance ( r D ) was positive and statistically significant in these
estimates,  r D  was assumed to be equal to zero for the purpose of the numerical computation, in
order to stay consistent with our treatment of antibiotic effectiveness as a depletable resource in
the analytical model.  Data on antibiotic prices were obtained from the MediSPAN
￿ database.
The following equations describe the discrete time version of the model replicating (5.1),
(7.1), (7.2) and (8.3)-(8.5). h represents the rate of recovery from a susceptible infection under
antibiotic treatment, both antibiotics have costs and recall that  I S - =1 .
(15.1) [ ] t t t t t t t I h f w h f w r I I
2
2 , 2 , 1 , 1 , 1 1 b - - - - b + = +
(15.2) [ ] kh f khw f w w t t t t t , 1 , 1 , 1 , 1 1 , 1 1 - + = +
(15.3) [ ] h f hw f w w t t t t t , 2 , 1 , 21 , 2 1 , 2 1 - + = +
(15.4) ( ) [ ]
( ) I t t t t t t
t t t t t t t
c f c f c f w f w b
f w f w h I r
- - - + -
+ + + + - + = +
, 2 2 , 1 1 , 2 , 2 , 1 , 1
, 2 , 2 , 1 , 1 1 2 1 b b r j j
(15.5) ( ) [ ] [ ] t t t t t t t f I h b w kh f , 1 , 1 , 1 , 1 1 , 1 1 2 1 j r m m - - - - + = +18
(15.6) ( ) [ ] [ ] t t t t t t t f I h b w h f , 2 , 2 , 2 , 2 1 , 2 1 2 1 j r m m - - - - + = +
In the benchmark experiment, we considered two antibiotics with  1 = k  and identical costs.  The
initial effectiveness of antibiotic 1 (GENT) was assumed to be 0.81 (the 12-year median level of
antibiotic effectiveness in our data set (see Table 1)), in contrast with an assumed initial
effectiveness of antibiotic 2 (TOB) of 0.96 (again, see Table 1).  The optimal treatment rule was
to use only antibiotic 2, until the level of resistance to the two antibiotics was identical (Figure 3).
After this point, both antibiotics were used simultaneously.  The level of infection drops in
response to the introduction of antibiotics, but swings upwards as resistance increases.   Initially,
1 m increases at the discount rate (Figure 4).  2 1 m m =  at the point in time when antibiotic 1 is
brought into use,.  After this, both  1 m  and  2 m decrease over time.  Furthermore, the absolute
value of j increases as the level of infection goes down.  When the rate of infection starts
increasing (with decreasing antibiotic effectiveness), the cost of infection given by j decreases in
absolute value.
The behavior of  1 w  and  2 w  when  1 . 0 = k , in the second numerical computation is almost
identical to that in the previous experiment (Figure 5).  Here too, antibiotic 1 is used only after
resistance to the two antibiotics is identical.  Once antibiotic 1 is brought into use, the ratio of use
of antibiotic1 to that of antibiotic 2 is roughly ten to one, as one would expect.  The rental rate for
antibiotic 1 is higher than the rental rate for antibiotic 2, when both are used, because each
treatment draws down  1 w  less ( 1 . 0 = k ) than it does  2 w .  The movement of the co-state variables
over time is plotted in Figure 6.
The time paths for infection and its shadow cost can be explained as follows.  Initially, the
infection level drops in response to the introduction of antibiotics in the hospital.  The shadow
cost of infection, given by j , increases in response to the decrease in infection level
14.  This is
because with fewer infections, the marginal cost (both in terms of the direct cost and the cost
associated with decreasing the number of secondary infections) to the hospital of an additional
                                                       
14 Note that j  is non-positive.19
infected individual is greater.  However, as antibiotics lose effectiveness, the infection level starts
to go back up again, and the shadow cost of infection declines.
Costs are introduced in the third experiment (Figures 7 - 10).  Following the MediSPAN
®
data, the cost of antibiotic 2 is assumed to be $ 43 and the cost of antibiotic 1 is assumed to be $
0.96
15.  The marginal benefit of each successful treatment, b , is assumed to be $200
16.  In order
to focus on the role of costs, we assume the initial effectiveness of the two antibiotics to be
identical.  Figure 7 illustrates the optimal extraction path when the cost of the two antibiotics is
identical and set equal to zero, and is provided for comparison.  Here, the optimal policy is to use
to use both antibiotics simultaneously since they are perfect substitutes in both resistance profile
and economic costs.
Introducing economic costs modifies the biologically optimal solution in two respects.
First, if the cost of using one antibiotic is less than that of the second, then ceteris paribus, the
lower cost antibiotic will be used first.  The high cost antibiotic will be introduced only when the
marginal benefit of its superior effectiveness is equal to its relatively higher marginal cost of use.
This policy diverges from the conclusion in Bonhoeffer et. al. that two antibiotics should be used
simultaneously. When the role of costs is considered (in Figure 8), there is an initial period of time
(nine months in this case), during which only antibiotic 1 (lower cost antibiotic) is used
17.
Following this, both antibiotics are used simultaneously.
Second, the extent to which the low cost antibiotic will be preferred over the high cost
antibiotic is determined by the marginal net benefit of successful antibiotic treatment. The
divergence between the path of effectiveness of the two antibiotics when variable costs differ is
unmistakable in Figure 8, where b  is assumed to be $200.  On the other hand, if b  is large
                                                       
15 In 1997, the average wholesale price of gentamicin was $0.11/80mg and the average wholesale price of tobramycin was
$4.95/80mg, over the period from 1986-1997.  The mean aminoglycoside dose at Harborview Medical Center during this
period was approximately 700 mg.  Therefore, the total drug cost of treatment using gentamicin was $0.96.  The drug cost of
treatment using tobramycin was nearly 45 times as great at $43.31.  The costs of intravenously administering the two drugs
were similar.
16  We used this figure (b=$200) as a lower bound estimate in order to compare the optimal path for this case with the optimal
path when b=$2,000.  The $2,000 figure was mentioned by doctors at Harborview Medical Center as the lump-sum
reimbursement to the hospital from Medicare for treating most infectious disease related illnesses.
17 The length of this initial period, T  is sensitive to the value of k .  The elasticity of T  with respect to k  is –1, calculated
from (11).20
relative to antibiotic costs, then antibiotic costs play only a minor role.  In this case, both
antibiotics will be used simultaneously, even if the cost of using one antibiotic exceeds that of the
other.  The shadow value of antibiotic 2 (lower variable costs) decreases, and, as previously, the
shadow value of antibiotic 1 increases until both antibiotics are used (Figure 9).  Hereafter, both
1 m and  2 m decline.  When antibiotic costs,  1 c  and  2 c  are relatively small compared to the benefit
of successful therapy, b  (see Figure 10), the role of variable costs in selecting the less expensive
antibiotic over the more expensive one is somewhat diminished.
6. CONCLUSION AND EXTENSIONS
The problem of declining antibiotic effectiveness presents a classic case of resource extraction.
Antibiotic effectiveness can be treated as renewable or non-renewable depending on biological
and bio-chemical attributes of the bacteria and antibiotic under consideration. When we apply the
economic objectives of inter-temporal optimization to the biological model of resistance
dynamics, a number of results become apparent.
Antibiotics with greater effectiveness will be used before those with lesser effectiveness in
the same manner that low cost deposits will be extracted before high cost deposits (Weitzman,
1976).  This result contrasts with the conclusions in Bonhoeffer et. al. that both antibiotics should
be used simultaneously, a result obtained by disregarding economic costs.  In general, antibiotics
differ from each other, both in the rate at which they lose effectiveness and with respect to the
marginal cost of use.  If the rate at which bacteria acquire resistance to one antibiotic exceeds the
rate it acquires resistance with respect to another antibiotic, then it is optimal to use a smaller
fraction of the first such that the effectiveness of the two antibiotics is identical at all times.  The
marginal cost of an antibiotic includes the direct cost of the antibiotic, the cost of administering
the antibiotic, and the cost associated with side effects.  If two antibiotics have the same initial
effectiveness and the marginal cost of using one antibiotic exceeds another then the less expensive
antibiotic is used first.  This continues until the net marginal benefits of the two antibiotics are
identical.  From this point on, both antibiotics are used simultaneously.  These results are distinct21
from those found in the population biology and epidemiological literature in which economic
considerations play no role
18.
It is perhaps prudent to remind the reader that these results are conditional upon two
caveats.  First, we have assumed that there is no fitness cost associated with resistance
19.  A
forthcoming paper examines the case when the fitness cost is significant and antibiotic
effectiveness is treated as a renewable resource.  Second, our model treats a hospital as a closed
system and is therefore applicable only to nosocomial or hospital-acquired infections.  Therefore,
antibiotic effectiveness is, for all practical purposes, a private access resource from the perspective
of the hospital administrator.  In the case of community-acquired infections, antibiotic
effectiveness is more akin to an open access resource and a different model would be applicable
under those circumstances.
At the heart of the problem of antibiotic resistance is the issue of the externality imposed
by each beneficial use of antibiotics on their future effectiveness.  One potential economic solution
to the problem of divergence between the rate of antibiotic use in a decentralized situation and the
optimal rate can be corrected by imposing an optimal tax on antibiotics.  However, taxes may not
be the only mechanism at the social planner’s disposal.  Most hospitals use a formulary, a list of
antibiotics that are stocked in the pharmacy based on the recommendation of the infection control
committees.  The purpose of formularies is to give the hospital administration some control over
the prescribing patterns of its physicians. Since the menu of antibiotics available to a physician is
based on the composition of the formulary at that time, a central (hospital) planner can alter the
fraction of patients treated with a given antibiotic by altering the composition of the formulary.
The above measures to encourage the optimal use of antibiotics are distinct from those
that discourage the misuse of antibiotics for unnecessary prophylaxis and to treat viral infections
(which cannot be cured using antibiotics).  The absence of incentives for pharmaceutical firms to
take antibiotic resistance into account when making pricing decisions in a competitive market
characterized by threat of entry by similar antibiotics is a subject for another paper.  Finally, the
                                                       
18 The potential for divergence between economic results and results from purely epidemiological models has been noted by
other researchers in this field (Philipson, 1999).
19 Although Bonhoeffer et. al introduce the notion of fitness cost in their model, fitness cost is set equal to zero throughout.22
use of antibiotics in cattle and poultry feed continues to be a contentious issue that is unlikely to
be resolved any time soon.23
APPENDIX  1
Let  1 I ,  2 I , and  12 I  represent fractions of the infected population that are resistant to only
antibiotic 1, only antibiotic 2, and both antibiotics 1 and 2, respectively.  Then,
A.1.1 w I I I I I + + + = 12 2 1
where  w I is the fraction of the infected population that is susceptible to both antibiotics.  The
equations of motion that describe the four categories of the infected population are as follows:
A.1.2 ( ) w w w w w I f f I r SI I 2 1 + - - = b &
1 2 1 1 1 1 I f I r SI I - - = b &
2 1 2 2 2 2 I f I r SI I - - = b &
12 12 12 12 I r SI I - = b &
1 f  and  2 f  are the fractions of the infected population treated with antibiotics 1 and 2.  We
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w I I I I I & & & & & + + + = 12 2 1
Substituting for  w I ,  1 I ,  2 I , and  12 I  we get
A.1.3 ( ) ( ) ( ) 12 2 1 12 12 12 1 2 12 2 1 2 2 1 1 1 w w w r w r w w r w w r f w f w S
I
I
w + - - - - - - - - - - = b
&
A.1.4 ( ) ( ) ( ) 12 12 2 1 12 12 1 2 2 12 2 1 1 r r r r r w r r f w r r f w S
I
I
w - - - + + - + - - + - = b
&
If  r r r r r w = = = = 12 2 124
A.1.5 r f w f w S
I
I
- - - = 2 2 1 1 b
&





































I w w & & &
2 2
A.1.6 ( ) [ ] [ ][ ] 12 1 1 2 12 2 1 w w f r S w f f r S w - - - + + - - = b b
( ) ( ) ( ) [ ] 12 2 1 12 12 12 1 2 12 2 1 2 2 1 1 1 1 w w w r w r w w r w w r f w f w S w w + - - - - - - - - - - b -
If  r r r r r w = = = = 12 2 1
A.1.7 ( ) ( ) 2 1 12 2 1 1 1 1 1 w w w f w w f w - - - = &
By symmetry,
A.1.8 ( ) ( ) 2 1 12 1 2 2 2 2 1 w w w f w w f w - - - = &
For low levels of multi-drug resistance and negligible cross-resistance,
A.1.9 ( ) 1 1 1 1 1 - = w w f w &
A.1.10  ( ) 1 2 2 2 2 - = w w f w &25
APPENDIX 2
When antibiotic 1 is being used, from equation (8.3), we have













- - - =
&
Substituting (8.1) into (4.2) yields
A.2.2 1 1
1
1 w kf - = r
m
m &
Differentiating equation (8.1) with respect to time,
A.2.3 ( ) ( ) ( )
( ) 1 1




w kw Iw w I b w I b
-
- + - - + -
=




Substitute for  1 m & from equation (A.2.2) and for 1 w & , I & , j &  from equations (5.1), (7.1) and (8.5) to
get,
A.2.4 ( ) ( ) r b j b - - = + r b b I
as long as the disease is not eradicated ( ) 0 > I  and  1 = k .  Rewriting this condition as









we see that  0 < j when 
b
r b - -
>
r
I .  That this condition holds is fairly intuitive from a
biological standpoint.  The basic necessary condition for the disease to not be naturally eradicated





‡  in the natural world.
Therefore, for a positive discount rate r , 
b
r b - -
>
r
I  must hold.
From equation 8.5,
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Since j < 0,  ( )
j
j 1 f c c wf b I + + -























In this appendix, we prove that  2 1 w w = , when both antibiotics are used and antibiotics costs are
assumed to be zero.  Assume  2 1 w w > .  More specifically, let  q + = 2 1 w w .  Then the necessary
condition for both antibiotics to be used simultaneously is given by
A.3 ( ) ( ) 2 2 1 1 1 1 w z w k z - - = - - m m
where  ( )I b z j - =
We can write this as
A.3.1 ( ) ( ) 2 2 2 1 1 1 w w k - = - - m q m
Differentiating with respect to time, we get
























From a solution of equations (8.1)-(8.4), we obtain
A.3.3 1 1
1





















From equations A.3.2 and A.3.5 we get
A.3.6 ( )



















It is trivial to show that the first term on the left hand side cancels out the first term on the right if
we substitute for  2 w & .  The other two terms can be written as
A.3.7 ( ) q q - - - = + 2 1 1 2 1 w w kf w & &
Substituting for  2 w & and  1 w  and expanding, we get
A.3.8 ( )( ) q q q - - + - = + - 2 2 1 2 2
2
2 2 1 w w kf w f w f &
A.3.9 ( ) ( ) ( ) ( ) q q q q - + - + = + -
2




2 2 1 2 kf kf w kf w w f w f &
Equating coefficients of 
2
2 w ,  2 w  and 1 on both sides, we get
A.3.10 2 1 f kf =
A.3.11 0 1 1 2 = ￿ - = - q q
A.3.12 ( ) 0
2
1 = - = q q q kf &27
Therefore, we have established that if two antibiotics are used simultaneously, then it must be true
that  2 1 f kf =  and  2 1 w w = .  From equation (A.3.1) and the condition that  2 1 w w = , we also get
2 1 m m = k .28
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Figure 1: The SIS Model of Infection
Figure 2: Optimal Paths of Effectiveness
 SUSCEPTIBLE   INFECTIOUS
rI




( ) 0 1 w
1 w
( ) 0 2 w
1 1 = f
1 2 = f30
Table 1: Parameters used in numerical computations
Coefficient of disease transmission,   b 0.01
Social discount rate
20,  r 0.004
Rate of recovery from antibiotic treatment
21, h 2.55
Initial effectiveness of GENT,  ( ) 0 GENT w
0.81
Initial effectiveness of TOB,  ( ) 0 TOB w
0.96
Marginal benefit of successful antibiotic treatment, x $200 (Low)
$2,000 (High)
Marginal cost of GENT,  GENT c
$0.96
Marginal cost of TOB,  TOB c
$43
                                                       
20 We used a annual social discount rate of 5% that corresponds to the monthly rate expressed in the table.
21 This parameter is the inverse of the mean duration of bacterial colonization under antibiotic treatment for susceptible
infections and corresponds to a mean of 11 days of colonization.31


































































































































































































































































































































































































Figure 8:  Infection and antibiotic effectiveness















































































































Figure 7:  Infection and antibiotic effectiveness


















































































































































































































Figure 10:  Infection and antibiotic effectiveness
(k=1, with costs, b=2000)
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